Effects of sulfasalazine treatment on serum immunoglobulin levels in children with juvenile chronic arthritis

Reference

• McConkey B, Amos RS, Durham S, Forster PJG, Hubball S, Walsh L. Sulphasalazine in rheumatoid arthritis. Br Med J 1980;280:442–4.
   PubMed Web of Science ®Google Scholar
• Pinals RS, Kaplan SB, Lawson JG, Hepburn B. Sulfasalazine in rheumatoid arthritis: a double-blind, placebo-controlled trial. Arthritis Rheum 1986;29:1427–34.
   PubMedGoogle Scholar
• Nuver-Zwart IH, Riel PLCM van, Putte LBA van de, Gribnau FWJ. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthri-tis: evidence of an earlier effect of sulphasalazine. Ann Rheum Dis 1989;48:389–95.
   Google Scholar
• Hannonen P, Mottönen T, Hakola M, Oka M. Sulfasalazine in early rheumatoid arthritis: a 48 week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1992;36:1501–9.
   Google Scholar
• Ozdogan H, Turunc M, Defined B, Yurdakul S, Yazici H. Sulphasalazine in the treatment of juvenile rheumatoid arthritis: a preliminary open trial. J Rheumatol 1986;13:124–5.
   Google Scholar
• Suschke HJ. Die Therapie der juvenilen chronischen Arthritis mit Sulfasalazin. Z Rheumatol 1987;46:83–5.
   PubMedGoogle Scholar
• Ansell BM, Hall MA, Loftus JK, Woo P, Neumann V, Harvey A, et al. A multicenter pilot study of sulphasalazine in juvenile chronic arthritis. Clin Exp Rheumatol 1991;9:201–3.
   Google Scholar
• Joos R, Veys EM, Mielants H, Werveke S van, Goemaere S. Sulfasalazine treatment in juvenile chronic arthritis: an open study. J Rheumatol 1991;18:880–4.
   Google Scholar
• Suschke HJ. Die Behandlung der juvenilen Spondylarthritis und der reaktiven Arthritis mit Sulfasalazin. Monatsschr Kinderheilkd 1992;140:658–60.
   PubMedGoogle Scholar
• Gedalia A, Barash J, Press J, Buskila D. Sulphasalazine in the treatment of pauciarticular-onset juvenile chronic arthritis. Clin Rheumatol 1993;12:511–4.
   PubMedGoogle Scholar
• Job-Deslandre C, Menkes CJ. Sulfasalazine treatment for juvenile spondylarthropathy. Rev R hum Engl Ed 1993;60:403–5.
   Google Scholar
• Imundo LF, Jacobs JC. Sulfasalazine therapy for juvenile rheumatoid arthritis. J Rheumatol 1996;23:360–6.
   PubMedGoogle Scholar
• Rossum MAJ van, Fiselier TJW, Franssen MJAM, Zwinderman AH, ten Cate R, van Suijlekom-Smit LWA, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Arthritis Rheum 1998;41:808–16.
   Google Scholar
• Rains CP, Noble S, Faulds D. Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 1995;50(1):137–56.
   Google Scholar
• Smedegärd G, Björk J. Sulfasalazine: mechanism of action in rheumatoid arthritis. Br J Rheumatol 1995;34 Suppl. 2:7–15.
   Google Scholar
• Veale DJ, Maple C, Kirk G, McLaren M, Belch JJF. Soluble cell adhesion molecules - P-selection and ICAM-1, and disease activity in patients receiving sulphasalazine for active rheumatoid arthritis. Scand J Rheumatol 1998;27: 296–9.
   Google Scholar
• Chalmers IM, Sitar DS, Hunter T. A one-year, open, prospective study of sulfasalazine in the treatment of rheumatoid arthritis: adverse reactions and clinical response in relation to laboratory variables, drug and metabolite serum levels, and acetylator status. J Rheumatol 1990;17:764–70.
   Google Scholar
• Fan M, Kitas GD, Tunn EJ, Bacon PA. Immunodeficiencies associated with sulphasalazine therapy in inflammatory arthritis. Br J Rheumatol 1991;30:413–7.
   PubMedGoogle Scholar
• Kanerud L, Norhagen Engstrom G, Tarkowski A. Evidence for differential effects of sulfasalazine on systemic and mucosal immunity in rheumatoid arthritis. Ann Rheum Dis 1995;54:256–62.
   PubMedGoogle Scholar
• Delamere JP, Farr M, Grindulis KA. Sulphasalazine induced selective IgA deficiency in rheumatoid arthritis. Br Med J 1983;286:1547–8.
   Google Scholar
• Farr M, Tunn E, Bacon PA, Smith DH. Hypogammaglobu-linaemia and thrombocytopenia associated with sulphasala-zine therapy in rheumatoid arthritis [letter]. Ann Rheum Dis 1985;44:723–4.
   PubMed Web of Science ®Google Scholar
• Ad Hoc Committee on Clinical Guidelines of the ACR. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996;39:723–31.
   PubMedGoogle Scholar
• Simon SH, Vliet Vlieland TPM, Dijkmans BAC, Bernelot Moens HJ, Janssen M, Hazes JMW, et al. Laboratory screening for side effects of disease modifying antirheumatic drugs in daily rheumatological practice. Scand J Rheumatol 1998;27:170–9.
   PubMedGoogle Scholar
• Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol 1998;25:1991–4.
   PubMedGoogle Scholar
• Laasila K, Leirisalo-Repo M. Side effects of sulphasalazine in patients with rheumatic diseases or inflammatory bowel disease. Scand J Rheumatol 1994;23:338–40.
   PubMed Web of Science ®Google Scholar
• Savilahti E. Sulphasalazine induced immunodeficiency. Br Med J 1983;287:759.
   PubMedGoogle Scholar
• Leickly FE, Buckley RH. Development of IgA and IgG2 subclass deficiency after sulfasalazine therapy. J Pediatr 1986;108: 4–81–2.
   Google Scholar
• Symmons DPM, Salmon M, Farr M, Bacon PA. Sulfasalazine treatment and lymphocyte function in patients with rheuma-toid arthritis. J Rheumatol 1988;15:575–9.
   PubMedGoogle Scholar
• Comer SS, Jasin HE. In vitro immunomodulatory effects of sulfasalazine and its metabolites. J Rheumatol 1988;15:580–6.
   PubMed Web of Science ®Google Scholar
• Imai F, Suzuki T, Ishibashi T, Tanaka M, Akiyama Y, Dohi Y. Effect of sulfasalazine on B cell hyperactivity in patients with reumatoid arthritis. J Rheumatol 1994;21:612–5.
   PubMed Web of Science ®Google Scholar
• Kanerud L, Scheynius A, Hafström I. Evidence of a local intestinal immunomodulatory effect of sulfasalazine in rheumatoid arthritis. Arthritis Rheum 1994;17:1138–45.
   Google Scholar
• Pelkonen P, Savilahti E, Mäkelä A. Persistent and transient IgA deficiency in juvenile rheumatoid arthritis. Scand J Rheumatol 1983;12:273–9.
   Google Scholar
• Liblau RS, Bach J. Selective IgA deficiency and autoimmu-nity. Int Arch Allergy Immunol 1992;99:16–27.
   PubMedGoogle Scholar
• Cassidy JT, Petty RE, Sullivan DB. Occurrence of selective IgA deficiency in children with juvenile rheumatoid arthritis. Arthritis Rheum 1977;20 Suppl 3:181–3.
   Google Scholar
• Lipnick RN, Tsokos GC, Magilavy DB. Immune abnormal-ities in the pathogenesis of juvenile rheumatoid arthritis. Rheum Dis Clin North Am 1991;17:843–57.
   PubMed Web of Science ®Google Scholar
• Grom AA, Giannini EH, Glass DN. Juvenile rheumatoid arthritis and the trimolecular complex (HLA, T cell receptor, and antigen). Arthritis Rheum 1994;37:601–7.
   PubMedGoogle Scholar
• Howe HS, So AKL, Farrant J, Webster ADB. Common variable immunodeficiency is associated with polymorphic markers in the human major histocompatibility complex. Clin Exp Immunol 1991;84:387–90.
   Google Scholar
• Gross S, Blaiss MS, Herrod HG. Role of immunoglobulin subclasses and specific antibody determinations in the evaluation of recurrent infection in children. J Pediatr 1992;121:516–22.
   Google Scholar
• Sanders LAM, Rijkers GT, Kuis W, Tenbergen-Meekes AJ, de Graeff-Meeder BR, Hiemstra I, et al. Defective anti-pneumococcal polysaccharide antibody response in children with recurrent respiratory tract infections. J Allergy Clin Immunol 1993;91:110–9.
   Google Scholar